ClinicalTrials.Veeva

Menu

Mandibular Advancement Device (MAD) in Pregnant Women With Obstructive Sleep Apnea (OSA) (OBMAD)

Henry Ford Health logo

Henry Ford Health

Status

Withdrawn

Conditions

Obstructive Sleep Apnea of Adult
Pregnancy Related

Treatments

Device: Mandibular advancement Device

Study type

Interventional

Funder types

Other

Identifiers

NCT06256640
15984-01

Details and patient eligibility

About

We propose a single-arm trial to test the patient uptake and preliminary efficacy of MAD in a sample of 10 pregnant women with mild-to-moderate OSA. Study outcomes include patient-reported symptoms and objectively assessed sleep parameters assessed before treatment, during and after 10 weeks of MAD intervention (during pregnancy) and postpartum.

Full description

The purpose of this study is to explore MAD as an alternative treatment option for OSA in pregnant women. We are recruiting a small number of 10 healthy pregnant women with uncomplicated OSA (absence of significant cardiovascular, metabolic or neurocognitive consequences) who, after being offered CPAP as the recommended standard treatment, prefer to use a MAD over CPAP. All patients are recruited from a single center. We would like to get a first impression on the comfort level of these women with the MAD and their self-reported compliance and any improvement of symptoms with treatment. Additionally, we would like to test efficacy in controlling OSA with pregnancy progression. Finally, we would like to derive overall treatment effectiveness of the MAD in pregnant women as defined as a combination of efficacy and compliance.

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Singleton pregnancy, gestational week 14-20.
  2. Age ≥ 18, English-speaking.
  3. Reliable internet access (questionnaires/surveys)
  4. Untreated mild to mild-moderate OSA defined as AHI between 5-20 events/hour on the most recent home sleep study
  5. No significant hypoxemia on the initial sleep study defined as SaO2 nadir ≥70% and SaO2 equal or less than 30 minutes ≥88%
  6. The sleep study must have been a home sleep test that uses Peripheral Arterial Tone signal for evaluation of apneic events. The home sleep test has to be a WatchPAT device (WatchPAT® Home Sleep Study Device | Itamar Medical Ltd.).
  7. No significant confounding comorbidities including restless leg symptoms and circadian disorders (shift work)
  8. BMI less or equal to 40 and neck size less or equal to 40 cm
  9. Good oral health with manual dexterity and at least 8 tooth per arch

Exclusion criteria

  1. High risk pregnancy (age >40y, superimposed preeclampsia, pre-existing cardiac disease, severe organ dysfunction such as liver or renal failure, any condition that requires anticoagulation), and any condition Dr. Pitts or Dr Smith deem serious risk to mother/fetus. Well controlled chronic hypertension and diabetes are allowed and will not be excluded.
  2. Dental exclusion criteria: Complete edentulous arch, ongoing oral rehabilitation, uncontrolled periodontal disease, ongoing orthodontic treatment or completed treatment in a period less than 5 years, temporomandibular dysfunction (active acute pain or limitations on mandibula movements of any kind), prior oropharyngeal surgery, maximum protrusion less 5 mm
  3. Significant acute health problems that are unrelated to pregnancy or dental diseases including unstable psychiatric disease
  4. Non-English speaking
  5. Unable to provide informed consent

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

Intervention
Experimental group
Treatment:
Device: Mandibular advancement Device

Trial contacts and locations

1

Loading...

Central trial contact

Susana Falardo; Miriam Jaziri, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems